Senores Pharmaceuticals Ltd
Thu 8/10/2026,15:59:8 | NSE : SENORES
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1389.60
Previous Close
₹ 1389.60
Volume
299845
Mkt Cap ( ₹ Cr)
₹ 6104.86
High
₹ 1393.20
Low
₹ 1311.20
52 Week High
₹ 1599.00
52 Week Low
₹ 700.75
Book Value Per Share
₹ 209.33
Dividend Yield
0.00
Face Value
₹ 10.00
What's Your Call?
Collective community sentiment on Senores Pharmaceuticals Ltd
Your Vote -
Buy
66.67%
Hold
25.00%
Sell
8.33%
66.67%
12 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
1325.60
5
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
5
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Senores Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Senores Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Senores Pharma. - Shareholders meeting
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholders meeting
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Senores Pharma. - Trading Window
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Senores Pharma. - General Updates
-
Senores Pharma. - Clarification On Movement In Volume
-
Senores Pharma. - Clarification sought from Senores Pharmaceuticals Ltd
-
Senores Pharma's Vadodara facility clears USFDA inspection with no GMP observations
-
Senores Pharma. - General Updates
-
Senores Pharma. - Successful Completion Of USFDA Inspection
-
Senores Pharma. - Reg. 34 (1) Annual Report.
-
Senores Pharma. - Copy of Newspaper Publication
-
Senores Pharma. - Shareholders meeting
-
Senores Pharma. - Business Responsibility and Sustainability Reporting (BRSR)
-
Senores Pharma. - Reg. 34 (1) Annual Report.
-
Senores Pharma. - Shareholder Meeting To Be Held On September 25, 2026 At 11:30 Am (IST)
-
Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharma. - Copy of Newspaper Publication
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Change in Management
-
Senores Pharma. - Appointment of Company Secretary and Compliance Officer
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Acquisition
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Acquisition
-
Senores Pharma. - Board Meeting Outcome for Senores Pharmaceuticals Limited Has Informed The Exchange Regarding Outcome Of Bo
-
Senores Pharma. - Updates
-
Senores Pharma. - Outcome of Board Meeting
-
Senores Pharma. - General Updates
-
Senores Pharma. - Appointment
-
Senores Pharma. - Giving guarantees/indemnity/ becoming a surety for third party
-
Senores Pharma. - Intimation For Giving Corporate Guarantee For Credit Facilities Availed By Apnar Pharma Private Limited, Su
-
Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Senores Pharma. - Shareholders meeting
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Senores Pharma. - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Senores Pharma. - Copy of Newspaper Publication
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharma. - Statement of deviation(s) or variation(s) under Reg. 32
-
Senores Pharma. - Statement of deviation(s) or variation(s) under Reg. 32
-
Senores Pharma. - Monitoring Agency Report
-
Senores Pharma. - Investor Presentation
-
Senores Pharma. - Press Release
-
Senores Pharma. - Appointment
-
Senores Pharma. - Outcome of Board Meeting
-
Senores Pharma. - Outcome of Board Meeting
-
Senores Pharma. - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue
-
Senores Pharma. - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Change in Management
-
Senores Pharma. - Financial Results For Quarter Ended June 30, 2026
-
Senores Pharma. - Board Meeting Outcome for Outcome Of Board Meeting
-
Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Senores Pharma. - Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial
-
Senores Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026
-
Senores Pharmaceuticals
-
Senores Pharmaceuticals Ltd
-
Senores Pharmaceuticals
-
Senores Pharmaceuticals Ltd
-
Senores Pharmaceuticals acquires ANDA for Roflumilast
Key fundamentals
Evaluate the intrinsic value of Senores Pharmaceuticals Ltd stockÂ
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 821.41 | 801.93 | 260.871 | 99.332 | 48.2313 |
| Liabilities | 821.41 | 801.93 | 260.871 | 99.332 | 48.2313 |
| Equity | 46.05 | 46.05 | 30.505 | 9.818 | 8.7422 |
| Gross Profit | -18.68 | -7.28 | -0.062 | -1.78 | 0.9342 |
| Net Profit | 20.25 | 3.69 | 0.814 | 1.199 | 0.293 |
| Cash From Operating Activities | -26.88 | -20.4 | -62.818 | -43.414 | -12.1977 |
| NPM(%) | 19.08 | 9.57 | 2.39 | 9.68 | 1.84 |
| Revenue | 106.09 | 38.54 | 34.006 | 12.382 | 15.8508 |
| Expenses | 124.77 | 45.82 | 34.068 | 14.162 | 14.9166 |
| ROE(%) | 2.1 | 0.38 | 0.08 | 0.12 | 0.03 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Senores Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 793.90 | -2.32 | 20.08 | 793.07 | -26.19 | 0.63 |
| Lotus Eye Hospital and Institute Ltd | 113.94 | -0.78 | 1627.71 | 2889.85 | 0.39 | 0.00 |
| Vaishali Pharma Ltd | 7.99 | -1.36 | 24.97 | 18129.00 | 15.42 | 0.00 |
| Astec Lifesciences Ltd | 714.75 | -4.47 | 0.00 | 3096.32 | -363.14 | 0.00 |
Company Info
Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.
Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.
Read More
Parent Organisation
Senores Pharmaceuticals Ltd.
Founded
26/12/2017
Managing Director
Mr.Swapnil Jatinbhai Shah
NSE Symbol
SENORESEQ
FAQ
The current price of Senores Pharmaceuticals Ltd is ₹ 1325.60.
The 52-week high for Senores Pharmaceuticals Ltd is ₹ 1393.20 and the 52-week low is ₹ 1311.20.
The market capitalization of Senores Pharmaceuticals Ltd is currently ₹ 6104.86. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Senores Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Senores Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Senores Pharmaceuticals Ltd shares.
The CEO of Senores Pharmaceuticals Ltd is Mr.Swapnil Jatinbhai Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
